Revolutionizing Therapeutics with AI: ZAKA Invests in Olio Labs
Summary
At ZAKA, we are committed to supporting groundbreaking innovations that have the potential to change the landscape of the tech or healthcare industry.We are excited to announce our recent investment in Olio Labs, a visionary company that is harnessing the power of artificial intelligence to transform the way we approach therapeutics. Olio Labs participated in the S23 Y Combinator batch, further solidifying their position as a rising star in the industry.Olio Labs is at the forefront of a transformative approach to therapeutics by utilizing AI to develop treatments that take into account the complex interactions of thousands of proteins in the human body. This approach offers several advantages, including synergy, reduced resistance, fewer side effects, and the ability to target multiple pathways simultaneously. Their approach has already shown promising results in animal models, with a significant reduction in appetite and associated nausea.The key to Olio Labs success lies in their AI-driven compute-experiment platform, which allows them to design and test trillions of combinations efficiently. Olio Labs aims to discover combinations for both existing drugs and novel targets, making their impact even more far-reaching.Founded by Dr. David Tingley and Dr. Tom Roseberry, with impressive backgrounds from Harvard, New York University, and Neuralink, Olio Labs boasts a team of experienced scientists and AI engineers.